# Adversarial verification verdict — mixed_phenotype_acute_leukaemia

1. DOSE LEAK: none. Grepped for mg/mg-m2/AUC/mg-kg/day-N/cycle-N/qN-week patterns and every
   commonly-used MPAL/ALL/AML drug name (imatinib, dasatinib, ponatinib, blinatumomab,
   inotuzumab, hyper-CVAD, vincristine, cytarabine, daunorubicin, methotrexate) — zero hits.
   Sidecar uses only drug/regimen *classes* (e.g. "ALL-type induction backbone", "BCR-ABL1-targeted
   tyrosine kinase inhibitor"), never named agents, doses, or numbered schedules.

2. UNGROUNDED CLAIMS: none rise to fabrication — every specific treatment claim (BCR-ABL1 TKI
   pairing, KMT2A high-risk/transplant threshold, ALL-based induction preference for
   non-BCR-ABL1/non-KMT2A MPAL, transplant-in-CR1 role, trial-enrollment recommendation) is
   explicitly and consistently tagged "(general oncology standard, not from DeVita's section on
   this disease)" rather than presented as DeVita-sourced. This is honest labeling, not
   fabrication — but it also means the "general oncology standard" claims are NOT independently
   verified against a primary source in this pass; the draft agent flagged this itself and I
   could not verify it either (grep of DeVita found no MPAL-specific management section to check
   against). Two items worth flagging for R1:
   - No survival/remission statistics are given (correctly omitted per draft's own note) — good.
   - No named trials/regimens are given (correctly omitted) — good.
   - The one substantive risk: the "general oncology standard" characterization of BCR-ABL1+/
     KMT2A-rearranged MPAL management is standard-of-care/NCCN-consistent knowledge but is
     asserted from training knowledge, not from a citable text in this job's corpus. Not
     "uncontroversial" enough to wave through silently — flag for a human with NCCN/BCSH access
     to spot-check before this reaches clinicians, but it is not egregious or invented
     specifics (no numbers, no named drugs).

3. CITATION: source line present at the end — "DeVita, Hellman, and Rosenberg's Cancer:
   Principles & Practice of Oncology, 12th ed." plus an NCCN mention for the general-standard
   material, name only, no page numbers. Compliant with format.

4. VERDICT: CLEAN (ready for R1), with one flag carried forward — the entire treatment-approach
   section rests on general-oncology-standard knowledge rather than a DeVita-grounded MPAL
   management section (DeVita has none), and R1 should independently confirm the
   BCR-ABL1-TKI-pairing / KMT2A-high-risk-transplant-threshold / ALL-preferred-induction claims
   against NCCN ALL/AML guidelines directly rather than accepting this sidecar's characterization
   at face value. No dose leak, no invented drug names, no invented trials/statistics — the
   fabrication risks this sidecar could have hit are all absent.
